Coloplast Management

Management Kriterienprüfungen 4/4

Coloplast's CEO ist Kristian Villumsen , ernannt in Dec 2018, hat eine Amtszeit von 5.5 Jahren. Die jährliche Gesamtvergütung beträgt DKK23.30M , bestehend aus 51.5% Gehalt und 48.5% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.045% der Aktien des Unternehmens, im Wert von DKK84.11M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 6.2 Jahre bzw. 6.4 Jahre.

Wichtige Informationen

Kristian Villumsen

Geschäftsführender

kr.23.3m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	51.5%
Amtszeit als Geschäftsführer	5.5yrs
Eigentum des Geschäftsführers	0.05%
Durchschnittliche Amtszeit des Managements	6.2yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	6.4yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Kristian Villumsen im Vergleich zu den Einnahmen von Coloplast verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Mar 31 2024	n/a	n/a	kr.5b
Dec 31 2023	n/a	n/a	kr.5b
Sep 30 2023	kr.23m	kr.12m	kr.5b
Jun 30 2023	n/a	n/a	kr.5b
Mar 31 2023	n/a	n/a	kr.5b
Dec 31 2022	n/a	n/a	kr.5b
Sep 30 2022	kr.21m	kr.12m	kr.5b
Jun 30 2022	n/a	n/a	kr.5b
Mar 31 2022	n/a	n/a	kr.5b
Dec 31 2021	n/a	n/a	kr.5b
Sep 30 2021	kr.22m	kr.11m	kr.5b
Jun 30 2021	n/a	n/a	kr.5b
Mar 31 2021	n/a	n/a	kr.4b
Dec 31 2020	n/a	n/a	kr.4b
Sep 30 2020	kr.20m	kr.11m	kr.4b
Jun 30 2020	n/a	n/a	kr.4b
Mar 31 2020	n/a	n/a	kr.4b
Dec 31 2019	n/a	n/a	kr.4b
Sep 30 2019	kr.17m	kr.10m	kr.4b
Jun 30 2019	n/a	n/a	kr.4b
Mar 31 2019	n/a	n/a	kr.4b
Dec 31 2018	n/a	n/a	kr.4b
Sep 30 2018	kr.11m	kr.6m	kr.4b
Jun 30 2018	n/a	n/a	kr.4b
Mar 31 2018	n/a	n/a	kr.4b
Dec 31 2017	n/a	n/a	kr.4b
Sep 30 2017	kr.10m	kr.6m	kr.4b

Vergütung im Vergleich zum Markt: KristianDie Gesamtvergütung ($USD3.35M) liegt unter dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt UK ($USD5.78M).

Entschädigung vs. Einkommen: KristianDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Kristian Villumsen (54 yo)

5.5yrs

Amtszeit

kr.23,300,000

Vergütung

Mr. Kristian Villumsen has been Independent Director of Demant A/S since March 5, 2021. He has been the President and Chief Executive Officer of Coloplast A/S since December 4, 2018. Mr. Villumsen was an E...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Kristian Villumsen	President & CEO	5.5yrs	kr.23.30m	0.045% DKK 85.6m
Anders Lonning-Skovgaard	Executive VP & CFO	9.9yrs	kr.11.90m	0.0012% DKK 2.2m
Allan Rasmussen	Executive Vice President of Global Operations	9.9yrs	kr.10.50m	0% DKK 0
Nicolai Andersen	Executive Vice President of Innovation	no data	kr.10.00m	keine Daten
Paul Marcun	Executive Vice President of Growth	5.4yrs	kr.12.00m	keine Daten
Thomas Barfod	Senior Controller & Employees Representative Director	no data	kr.450.00k	0.000020% DKK 38.0k
Ellen Bjurgert	Vice President of Investor Relations	7.7yrs	keine Daten	keine Daten
Dennis Kaysen	Director of Corporate Communications	no data	keine Daten	keine Daten
Dorthe Ronnau	Senior Vice President of People & Culture	2.4yrs	keine Daten	keine Daten
Alain Morvan	Senior Vice President of Sales Europe	12.2yrs	keine Daten	keine Daten
Rasmus Møller	Senior Vice President of Wound & Skin Care	3.8yrs	keine Daten	keine Daten
Manu Varma	Senior Vice President of Chronic Care - North America	6.2yrs	keine Daten	keine Daten

6.2yrs

Durchschnittliche Betriebszugehörigkeit

55yo

Durchschnittliches Alter

Erfahrenes Management: COLOBCDas Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (6.2 ).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Thomas Barfod	Senior Controller & Employees Representative Director	18.4yrs	kr.450.00k	0.000020% DKK 38.0k
Carsten Hellmann	Independent Director	6.5yrs	kr.690.00k	0.0027% DKK 5.1m
Lars Rasmussen	Chairman of the Board	5.5yrs	kr.1.84m	0.092% DKK 175.3m
Niels Louis-Hansen	Deputy Chairman	56.4yrs	kr.938.00k	1.93% DKK 3.7b
Marianne Wiinholt	Independent Director	3.5yrs	kr.880.00k	0.00022% DKK 418.1k
Jette Nygaard-Andersen	Independent Director	8.5yrs	kr.600.00k	keine Daten
Nikolaj Gundersen	Employees Representative Director	6.4yrs	kr.450.00k	keine Daten
Roland Pedersen	Employees Representative Director	6.4yrs	kr.450.00k	0.00072% DKK 1.4m
Annette Bruls	Independent Director	2.5yrs	kr.600.00k	keine Daten

6.4yrs

Durchschnittliche Betriebszugehörigkeit

59yo

Durchschnittliches Alter

Erfahrener Vorstand: COLOBCDie Vorstandsmitglieder gelten als erfahren (6.4 Jahre durchschnittliche Amtszeit).

Coloplast Management

Management Kriterienprüfungen 4/4

Wichtige Informationen

Jüngste Management Updates

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Recent updates

First half dividend of kr.5.00 announced

Second quarter 2024 earnings released: EPS: kr.5.57 (vs kr.5.44 in 2Q 2023)

Coloplast A/S Revises Earnings Guidance for the Fiscal Year 2023/24

Less than half of directors are independent

First quarter 2024 earnings released

Coloplast A/S Reaffirms Earnings Guidance for the Fiscal Year 2023/24

Less than half of directors are independent

Coloplast A/SLaunches Biatain® Silicone Fit for Pressure Injury Prevention and Wound Management in the US

Less than half of directors are independent

Coloplast A/S Approves the Distribution of Year-End Dividend

Less than half of directors are independent

Coloplast A/S Provides Earnings Guidance for Fiscal Year 2023-2024

Full year 2023 earnings released

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Coloplast A/S to Report Q1, 2024 Results on Feb 09, 2024

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

Deputy Chairman recently bought kr.40m worth of stock

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

Third quarter 2023 earnings released: EPS: kr.5.99 (vs kr.6.07 in 3Q 2022)

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/2023

Coloplast A/S (CPSE:COLO B) signed an agreement to acquire Kerecis, LLC for $1.3 billion.

Coloplast A/S Provides Earnings Guidance for the Fiscal 2023

Less than half of directors are independent

First quarter 2023 earnings released: EPS: kr.5.31 (vs kr.5.67 in 1Q 2022)

Coloplast Launches Male Catheter Designed to Reduce the Risk of Urinary Tract Infections

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/23

Upcoming dividend of kr.15.00 per share

Less than half of directors are independent

Coloplast Announces Executive Changes

Coloplast A/S Provides Financial Guidance for the Fiscal Year 2023

Coloplast Launches Saffron™ Fixation System for Prolapse Repair

Coloplast A/S to Report Fiscal Year 2023 Results on Nov 09, 2023

Third quarter 2022 earnings released

Coloplast A/S Provides Revenue Guidance for the Fiscal Year 2021-2022

Coloplast A/S Provides Earnings Guidance for the Full Year of 2022

Second quarter 2022 earnings released

Less than half of directors are independent

Contraline Names Yelena Tropsha as CTO

Coloplast A/S (CPSE:COLO B) completed the acquisition of Atos Medical AB from PAI Europe VI, L.P., managed by PAI Partners.

First quarter 2022 earnings: Revenues exceed analyst expectations

Coloplast A/S Updates Earnings Guidance for the Year 2021/22

Independent Director Birgitte Nielsen has left the company

Upcoming dividend of kr.14.00 per share

Full year 2021 earnings released: EPS kr.22.67 (vs kr.19.74 in FY 2020)

Third quarter 2021 earnings released: EPS kr.5.89 (vs kr.4.69 in 3Q 2020)

Coloplast A/S Provides Earnings Guidance for the Year 2020/2021

Coloplast A/S Provides Earnings for the Year 2021

Second quarter 2021 earnings released

New 90-day low: kr.857

First quarter 2021 earnings released

New 90-day high: kr.999

Revenue beats expectations

New 90-day low: kr.886

Coloplast A/S Elects Marianne Wiinholt as A New Member of the Board of Directors

Coloplast A/S (CPSE:COLO B) acquired Nine Continents Medical, Inc. for approximately $150 million.

Coloplast A/S to Report First Half, 2021 Results on May 06, 2021

Analyse der Geschäftsführervergütung

Geschäftsführer

Amtszeit

Vergütung

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter